Farnham PG - Search Results

1

Estimated Lifetime HIV-Related Medical Costs in the United States.

Bingham A, Shrestha RK, Khurana N, Jacobson EU, Farnham PG. Bingham A, et al. Among authors: farnham pg. Sex Transm Dis. 2021 Apr 1;48(4):299-304. doi: 10.1097/OLQ.0000000000001366. Sex Transm Dis. 2021. PMID: 33492100

2

Costs to business for an HIV-infected worker.

Farnham PG, Gorsky RD. Farnham PG, et al. Inquiry. 1994 Spring;31(1):76-88. Inquiry. 1994. PMID: 8168911

3

Estimating the value of preventing a human immunodeficiency virus infection.

Guinan ME, Farnham PG, Holtgrave DR. Guinan ME, et al. Among authors: farnham pg. Am J Prev Med. 1994 Jan-Feb;10(1):1-4. Am J Prev Med. 1994. PMID: 8172724

4

Defining and measuring the costs of the HIV epidemic to business firms.

Farnham PG. Farnham PG. Public Health Rep. 1994 May-Jun;109(3):311-8. Public Health Rep. 1994. PMID: 8190854 Free PMC article. Review.

5

Counseling and testing for HIV prevention: costs, effects, and cost-effectiveness of more rapid screening tests.

Farnham PG, Gorsky RD, Holtgrave DR, Jones WK, Guinan ME. Farnham PG, et al. Public Health Rep. 1996 Jan-Feb;111(1):44-53; discussion 54. Public Health Rep. 1996. PMID: 8610190 Free PMC article.

6

Human immunodeficiency virus retesting during pregnancy: costs and effectiveness in preventing perinatal transmission.

Sansom SL, Jamieson DJ, Farnham PG, Bulterys M, Fowler MG. Sansom SL, et al. Among authors: farnham pg. Obstet Gynecol. 2003 Oct;102(4):782-90. doi: 10.1016/s0029-7844(03)00624-0. Obstet Gynecol. 2003. PMID: 14551009

7

Updated estimates of healthcare utilization and costs among perinatally HIV-infected children.

Sansom SL, Anderson JE, Farnham PG, Dominguez K, Soorapanth S, Clark J, Sukalac T, Earp MJ, Bohannon B, Fowler MG; PSD Consortium. Sansom SL, et al. Among authors: farnham pg. J Acquir Immune Defic Syndr. 2006 Apr 1;41(4):521-6. doi: 10.1097/01.qai.0000191286.70331.7b. J Acquir Immune Defic Syndr. 2006. PMID: 16652063

8

The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences.

Hutchinson AB, Farnham PG, Dean HD, Ekwueme DU, del Rio C, Kamimoto L, Kellerman SE. Hutchinson AB, et al. Among authors: farnham pg. J Acquir Immune Defic Syndr. 2006 Dec 1;43(4):451-7. doi: 10.1097/01.qai.0000243090.32866.4e. J Acquir Immune Defic Syndr. 2006. PMID: 16980906

9

Comparing the costs of HIV screening strategies and technologies in health-care settings.

Farnham PG, Hutchinson AB, Sansom SL, Branson BM. Farnham PG, et al. Public Health Rep. 2008 Nov-Dec;123 Suppl 3(Suppl 3):51-62. doi: 10.1177/00333549081230S307. Public Health Rep. 2008. PMID: 19166089 Free PMC article.

10

Do reduced inpatient costs associated with highly active antiretroviral therapy (HAART) balance the overall cost for HIV treatment?

Farnham PG. Farnham PG. Appl Health Econ Health Policy. 2010;8(2):75-88. doi: 10.2165/11531890-000000000-00000. Appl Health Econ Health Policy. 2010. PMID: 20175587

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

56 results

Search Page

Filters